Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Table 2

Association between SALL4 expression and clinicopathologic characteristics in HCC.

Variables	SALL4 expression		𝑃
	Positive	Negative
	(score = 1–4)	(score = 0)
	𝑛=18 (%)	𝑛=20 (%)
Age (y)	50.83±10.33	54.31±14.19	0.392
Sex
Male	17 (94)	18 (90)	1.000
Female	1 (6)	2 (10)
Tumor size (cm)	5.44±2.71	6.67±3.01	0.135
Histologic grade
Well differentiated	3 (17)	0 (0)	0.101
Moderately differentiated	13 (72)	14 (70)
Poor differentiated	2 (11)	6 (30)
Tumor focality
Solitary	15 (83)	19 (95)	0.328
Multiple	3 (17)	1 (5)
Nodal metastasis
Present	2 (11)	4 (20)	0.663
Absent	16 (89)	16 (80)
Vascular invasion
Present	4 (22)	8 (40)	0.307
Absent	14 (78)	12 (60)
T-grade
T1-T2	11 (61)	6 (30)	0.101
T3-T4	7 (39)	14 (70)
Stage
I-II	11 (61)	14 (70)	0.734
III-IV	7 (39)	6 (30)